-
1.发明授权公开(公告)号：US06245747B1
公开(公告)日：2001-06-12
申请号：US09114399
申请日：1998-07-13
IPC分类号： A01N4304
CPC分类号： A61K9/0009 , A61K9/0019 , A61K9/5015 , A61K9/5052 , A61K41/0028 , A61K47/6925 , C12N15/1135 , C12N15/87 , C12N2310/315
摘要： The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in utility for agents such as oligonucleotides which are plagued with problems in reaching targeted sites in necessary therapeutic levels. The delivery system includes gas-filled microbubbles formed in a nitrogen-free environment. Microbubbles formed through sonication in a nitrogen-free environment are smaller and more stable than microbubbles sonicated in the presence of room air.
摘要翻译： 本发明涉及用于递送治疗剂的新的和改进的药物组合物和方法。 本发明的方法和组合物可以与几种治疗剂一起使用，并且可以实现治疗物质的位点特异性递送。 这可以允许较低的剂量和用于改善传统上达到目标部位的药物的功效，并且可以导致药物如寡核苷酸的用途，所述药物如在需要治疗水平达到目标部位时遇到问题的寡核苷酸。递送系统包括形成的充气微泡 在无氮环境中。 在无氮环境中通过超声处理形成的微泡比在室内空气存在下超声处理的微泡更小，更稳定。
-
2.发明授权Compositions and methods for altering the biodistribution of biological agents 有权用于改变生物制剂生物分布的组合物和方法公开(公告)号：US06537814B1
公开(公告)日：2003-03-25
申请号：US09591380
申请日：2000-06-09
IPC分类号： C12N1563
CPC分类号： A61K41/0028 , A61K47/6925 , A61K49/223
摘要： The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
摘要翻译： 本发明涉及用于递送治疗剂的新的和改进的药物组合物和方法。 本发明的方法和组合物可以与几种治疗剂一起使用，并且可以实现治疗或诊断物质的位点特异性递送。 这可以允许较低剂量和用于改善传统上达到目标部位的药物的功效，并且可以导致药物如寡核苷酸和多核苷酸的改善效用，这些药物受到生物分布问题的困扰。
-
公开(公告)号：US6117858A
公开(公告)日：2000-09-12
申请号：US118168
申请日：1998-07-17
IPC分类号： A61K47/42 , A61K9/48 , A61K38/00 , A61K41/00 , A61K47/48 , A61K48/00 , A61K49/22 , A01N51/00
CPC分类号： A61K41/0028 , A61K47/48869 , A61K49/223
摘要： The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
-
公开(公告)号：US07115583B2
公开(公告)日：2006-10-03
申请号：US10355388
申请日：2003-01-31
CPC分类号： A61K41/0028 , A61K47/6925 , A61K49/223
摘要： The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
摘要翻译： 本发明涉及用于递送治疗剂的新的和改进的药物组合物和方法。 本发明的方法和组合物可以与几种治疗剂一起使用，并且可以实现治疗或诊断物质的位点特异性递送。 这可以允许较低剂量和用于改善传统上达到目标部位的药物的功效，并且可以导致药物如寡核苷酸和多核苷酸的改善效用，这些药物受到生物分布问题的困扰。
-
5.发明授权Compositions and methods for altering the biodistribution of biological agents 失效用于改变生物制剂生物分布的组合物和方法
公开(公告)号：US5849727A
公开(公告)日：1998-12-15
申请号：US670999
申请日：1996-06-28
IPC分类号： A61K47/42 , A61K9/48 , A61K38/00 , A61K41/00 , A61K47/48 , A61K48/00 , A61K49/22 , A01N51/00
CPC分类号： A61K41/0028 , A61K47/48869 , A61K49/223
摘要： This invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic or bioactive agents. The methods and composition of the invention can be used with several therapeutic or bioactive agents and can achieve site-specific delivery of a therapeutic or biologically-active substance. This can allow for lower doses and for improved efficacy with drugs, particularly agents such as oligonucleotides which are plagued with problems in achieving therapeutic levels at targeted sites.
摘要翻译： 本发明涉及用于递送治疗或生物活性剂的新的和改进的药物组合物和方法。 本发明的方法和组合物可以与几种治疗或生物活性剂一起使用，并且可以实现治疗或生物活性物质的位点特异性递送。 这可以允许较低的剂量和用于药物，特别是诸如寡核苷酸的药物的改善效果，这些药剂在靶点上达到治疗水平方面存在问题。
-
6.发明授权Compositions and methods for altering the biodistribution of biological agents 有权用于改变生物制剂生物分布的组合物和方法公开(公告)号：US07198949B2
公开(公告)日：2007-04-03
申请号：US10668448
申请日：2003-09-22
CPC分类号： A61K41/0028 , A61K47/6925 , A61K49/223
摘要： The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
摘要翻译： 本发明涉及用于递送治疗剂的新的和改进的药物组合物和方法。 本发明的方法和组合物可以与几种治疗剂一起使用，并且可以实现治疗或诊断物质的位点特异性递送。 这可以允许较低剂量和用于改善传统上达到目标部位的药物的功效，并且可以导致药物如寡核苷酸和多核苷酸的改善效用，这些药物受到生物分布问题的困扰。
-
公开(公告)号：US10100305B2
公开(公告)日：2018-10-16
申请号：US14232858
申请日：2012-07-13
申请人： Patrick L. Iversen
发明人： Patrick L. Iversen
IPC分类号： C12N15/11 , C12N15/113
摘要： Provided herein are antisense oligonucleotides, compositions comprising antisense oligonucleotides, and methods for the use of antisense oligonucleotides in manipulating translation. Expression of isoforms of proteins expressed from different start codons of the same transcript are inhibited by antisense oligonucleotides, which may also enhance expression of non-target isoforms.
-
公开(公告)号：US08785410B2
公开(公告)日：2014-07-22
申请号：US12983798
申请日：2011-01-03
IPC分类号： C07H21/00
CPC分类号： C12N15/1136 , A61K31/675 , A61K47/645 , C07H21/00 , C07K7/08 , C12N2310/11 , C12N2310/31 , C12N2310/3145 , C12N2310/3233 , C12N2310/3513 , C12N2320/30 , C12Q1/6876 , C12Q2600/158 , Y10T436/143333
摘要： A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.
摘要翻译： 公开了一种用于治疗人类受试者骨骼肌质量不足的方法和化合物。 该组合物是吗啉代亚基的低聚物和将一个亚基的吗啉代氮连接到相邻亚单位的5'环外碳的含磷亚基间键，含有10-40个核苷酸碱基之间，具有有效地与表达杂交的碱基序列 经处理或预处理的人肌生成抑制素RNA转录物的敏感区域，以其加工形式由SEQ ID NO：6鉴定，并且能够被摄体中的靶肌细胞摄取。 在实施该方法中，化合物以量和剂量方案施用以产生在患者体内测量的血清肌生成抑制素水平的总体降低，优选使肌生成抑制素水平在正常健康个体确定的范围内 。
-
9.发明授权Antisense antiviral compound and method for treating influenza viral infection 有权反义抗病毒化合物及治疗流感病毒感染的方法公开(公告)号：US08697858B2
公开(公告)日：2014-04-15
申请号：US12945081
申请日：2010-11-12
申请人： Patrick L. Iversen
发明人： Patrick L. Iversen
IPC分类号： C07H21/04
CPC分类号： C07F9/65616 , A61K31/165 , A61K31/43 , A61K31/5377 , A61K31/545 , A61K31/7056 , A61K38/08 , A61K38/10 , C07K7/06 , C07K7/08 , C12N15/113 , C12N15/1131 , C12N2310/11 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3233 , C12N2310/3513 , C12N2310/3521
摘要： The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 30 bases of the 5′ or 3′ terminus of the positive sense vcRNA; c) the 45 bases surrounding the AUG start codon of an influenza viral mRNA and; d) 50 bases surrounding the splice donor or acceptor sites of influenza mRNAs subject to alternative splicing.
摘要翻译： 本发明涉及反义抗病毒化合物及其在抑制正粘病毒科的病毒生长和用于病毒感染治疗中的用途和生产方法。 该化合物特别可用于治疗哺乳动物的流感病毒感染。 示例性的反义抗病毒化合物是基本上不带电荷或部分带正电荷的吗啉代寡核苷酸，其具有1）核酸酶抗性主链，2）12-40个核苷酸碱基，和3）与目标区域杂交的至少12个碱基长度的靶向序列 选自以下：a）流感病毒A，流感病毒B和流感病毒C的阴性病毒RNA区段的5'或3'末端25个碱基; b）阳性vcRNA的5'或3'末端的末端30个碱基; c）流感病毒mRNA的AUG起始密码子周围的45个碱基; d）围绕可变剪接的流感mRNA的剪接供体或受体位点周围的50个碱基。
-
10.发明授权Antisense oligomers and methods for inducing immune tolerance and immunosuppression 有权反义寡聚体和诱导免疫耐受和免疫抑制的方法公开(公告)号：US08415313B2
公开(公告)日：2013-04-09
申请号：US11433033
申请日：2006-05-11
CPC分类号： A61K31/675 , C12N15/1138 , C12N2310/11 , C12N2310/3233 , C12N2310/3513
摘要： A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, containing 12-40 subunits and a base sequence effective to hybridize to a target region within the sequence identified by SEQ ID NO:9, to form a duplex structure between the compound and transcript having a Tm of at least 45° C. Formation of the duplex blocks expression of full-length CD86 in the cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.
摘要翻译： 公开了一种用于将人树突状细胞诱导到T细胞的抗原特异性激活能力降低的条件下，并且在成熟树突状细胞中细胞外IL-10的产生增加的方法和组合物。 将一群树突状细胞暴露于包含部分带正电荷的基本上不带电荷的反义化合物，其含有12-40个亚单位和碱基序列，其有效地与SEQ ID NO：9所鉴定的序列内的靶区域杂交以形成双链体 化合物和具有至少45℃的Tm的转录物之间的结构。双链体阻断细胞中全长CD86的表达，这又导致T细胞抗原特异性激活的能力降低，并且在 成熟的树突状细胞，细胞外IL-10的产生增加。
-
-
-
-
-
-
-
-
-
搜索结果
108 条记录 (耗时 0.037 秒)
